As Amgen Inc.’s Imdelltra (tarlatamab) pushes into the first-line setting for small-cell lung cancer, a fast-growing field of ...

Pricing the first biopharma IPO in the month of September, precision medicine company Electra Therapeutics Inc. is raising $350 million to advance the phase II/III registrational development of novel ...

Total biopharma financings through August 2026 reached $77.13 billion for the year, closely matching 2024's $77.52 billion ...

Even as the treatment potential for GLP-1 drugs continues to expand beyond metabolic indications, recognition grows for the ...

Sino Biopharmaceutical Ltd. has moved two internally developed assets closer to commercialization in China, with the Center for Drug Evaluation accepting NDAs for HER2 dual-epitope bispecific antibody ...

Increasing the pool of cancer patients that can benefit from immunotherapy is one of the major goals of the field as a whole. Researchers from Apeximmune Therapeutics Inc. and Erasmus Medical Center ...

Fempulse Corp. has received CE mark certification under the EU’s Medical Device Regulation for its Fempulse Ring to treat ...

Beijing Changping Laboratory has identified drug conjugates comprising polypeptides targeting ephrin type-A receptor 2 (EPHA2) covalently bound to radiolabeled metal complexed chelating agent through ...

The pause of trials with Kv7 potassium channel opener azetukalner in other indications cast a pall over the better news from Xenon Pharmaceuticals Inc. that the firm has submitted an NDA to the U.S.

A year after launching with a $65 million series A investment, Dualitas Therapeutics Inc. has signed up its first partner, Roche Holding AG, to use its Dualscreen Bispecific Discovery Engine to screen ...

Neovascular age-related macular degeneration (nAMD) is a major cause of severe vision loss driven by choroidal neovascularization (CNV), hemorrhage, photoreceptor loss and subretinal fibrosis. In a ...